| Name | Title | Contact Details |
|---|
Universal Rhblttion Ftnes Inst is a Livingston, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.
Complete Healthcare Communications Inc is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
National Clinical Research is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.